Novartis to Acquire Tourmaline Bio, Expanding Cardiovascular Pipeline

Novartis has announced its agreement to acquire New York-based biopharmaceutical company Tourmaline Bio for approximately USD 1.4 billion, at USD 48 per share. Tourmaline is advancing pacibekitug, a clinical-stage anti-IL-6 monoclonal antibody aimed at treating atherosclerotic cardiovascular disease (ASCVD) by reducing systemic inflammation, a key driver of cardiovascular risk.

Complementing Novartis’ Cardiovascular Strategy

Pacibekitug is positioned as a potential breakthrough therapy addressing residual inflammatory risk in ASCVD. With Phase 2 trials showing up to 86% reduction in high-sensitivity C-reactive protein (hs-CRP) and a favorable safety profile, the therapy provides a promising addition to Novartis’ cardiovascular portfolio. The acquisition allows Novartis to advance a Phase 3-ready asset, strengthening its leadership in cardiovascular care.

Market and Patient Impact

The acquisition enhances Novartis’ potential to deliver innovative anti-inflammatory therapies for ASCVD, addressing an unmet clinical need. With convenient dosing options, pacibekitug could improve patient adherence and outcomes, marking a significant step forward in managing cardiovascular risk globally.